You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Screen for hepatitis B virus in all cancer patients starting systemic treatment. Find out more about hepatitis B virus screening and management.

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.

Regimens

39 Items
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative
Jul 2023
Intent: Palliative
May 2019
Intent: Palliative
Funding:
New Drug Funding Program
    Tebentafusp (Outpatient) - Unresectable or Metastatic Uveal Melanoma
Jan 2024
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Feb 2024
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
New Drug Funding Program
    Temsirolimus - Metastatic Renal Cell Carcinoma
Jul 2020
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Jun 2019
Cancer Type:
Genitourinary, 
Testis
Intent: Curative
Mar 2021
Cancer Type:
Gynecologic, 
Germ Cell
Intent: Curative
Mar 2021
Cancer Type:
Genitourinary, 
Penile
Intent: Neoadjuvant, Palliative
Mar 2021
Intent: Palliative
Funding:
ODB - General Benefit
    tamoxifen
May 2022
Intent: Adjuvant
Funding:
ODB - General Benefit
    tamoxifen
Jun 2022
Cancer Type:
Gynecologic, 
Endometrial, 
Ovary
Intent: Palliative
Funding:
ODB - General Benefit
    tamoxifen
May 2022

Pages